

Amendments to the Specification

Please amend the specification as shown.

Please delete paragraph [0034] and replace it with the following paragraph:

[0034] In one embodiment, an α helix region of the invention can be represented by (α helix region type I) R1-VL Xaa10 Xaa11 LSQ Xaa15 L Xaa17 Xaa18 LQT Xaa22 P Xaa24 TNT-R1 (SEQ ID NO:29), wherein

Xaa10 is Gly or Aib;

Xaa11 is Lys, Arg, Orn, hArg, Cit, hLys, or Lys(for);

Xaa15 is Glu or Phe;

Xaa17 is His or Aib;

Xaa18 is Lys, Arg, Orn, hArg, Cit, hLys, Lys(for), Lys(PEG 5000);

Xaa22 is [[Try]]**Tyr** or Leu;

Xaa24 is Arg or Pro; or

R1 is absent or comprises 1-4 additional amino acids.

Please delete paragraph [0050] and replace it with the following paragraph:

[0050] In yet another aspect, compounds of the invention comprise an amino acid sequence comprising

a) a loop region comprising Xaa1;

b) an α helix loop type I; and

c) a C-terminal tail;

wherein X1 comprises an amino sequence of X Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Y

(SEQ ID NO:[[5]]**138**) wherein,

Xaa2 is any amino acid or absent;

Xaa3 is Ala, Gly, Ser, Asp or absent;

Xaa4 is Asn, Ala, Asp, Gly or absent;

Xaa5 is Ala, Leu, Thr, or Ser;

Xaa6 is Ala, Ser, or Thr; and

Xaa7 is Ala, Ser, Val, Hse, (S)-2-amino-3-hydroxy-methylbutanoic acid (Ahb), (2S,3R)-2-amino-3-hydroxy-methylpentanoic acid (Ahp), D-Thr, Thr, or a derivative thereof;

X and Y are amino acids capable of creating a bond and are independently selected residues having side chains which are chemically bonded to each other to form an intramolecular linkage such as disulfide bonds; amide bond; alkyl acids and alkyl amines which may form cyclic lactams; alkyl aldehydes or alkyl halides and alkylamines which may condensed and be reduced to form an alkyl amine or imine bridge; or side chains which may be connected to form an alkyl, alkenyl, alkynyl, ether or thioether bond;

the α helical region type I comprises the sequence R1-V L Xaa10 Xaa11 L S Q Xaa15 L Xaa17 Xaa18 L Q T Xaa22 P Xaa24 T N T-R1 (SEQ ID NO:29), wherein

Xaa10 is Gly or Aib;

Xaa11 is Lys, Arg, Orn, hArg, Cit, hLys, or Lys(for);

Xaa15 is Glu or Phe;

Xaa17 is His or Aib;

Xaa18 is Lys, Arg, Orn, hArg, Cit, hLys, Lys(for), Lys(PEG 5000);

Xaa22 is [[Try]]**Tyr** or Leu;

Xaa24 is Arg or Pro; or

R1 is absent or comprises 1-4 additional amino acids; and

the C-terminal tail comprises the sequence Xaa28 Xaa29 Xaa30 Xaa31 Xaa32 Xaa33 G Xaa35 Xaa36 Xaa37 Xaa38 (SEQ ID NO:31), wherein

Xaa28 is Lys, Tyr, or absent;

Xaa29 is Ser, Pro, or absent;

Xaa30 is Ser, Pro, Arg, or absent;

Xaa31 is Thr, or absent;

Xaa32 is Asn or absent;

Xaa33 is Val, Thr, or absent;

Xaa35 is Ser, Glu

Xaa36 is Asn, Lys, or Gly;

Xaa37 is Thr, Phe, or Ala;

Xaa38 is Tyr, Phe, Pro, or absent;

with the proviso that when the loop region is from a calcitonin or calcitonin analog and the α

helix region is from a calcitonin or calcitonin analog, the last position of the C-terminal tail is not Pro, Hyp, homoSerine (Hse) or derivatives of Hse.

After page 77 of the specification and prior to the claims, please enter the sequence listing provided herewith.